The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.
about
Cytokine synergy: an underappreciated contributor to innate anti-viral immunityM062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cellsTargeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.Pseudogenization of the MCP-2/CCL8 chemokine gene in European rabbit (genus Oryctolagus), but not in species of Cottontail rabbit (Sylvilagus) and Hare (Lepus).Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.Gene delivery of a viral anti-inflammatory protein to combat ocular inflammationOncolytic Poxviruses.Comparative analysis of poxvirus orthologues of the vaccinia virus E3 protein: modulation of protein kinase R activity, cytokine responses, and virus pathogenicityAn overview of the lagomorph immune system and its genetic diversity.Oncolytic myxoma virus: the path to clinicMyxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion.The current status and future directions of myxoma virus, a master in immune evasion.Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.Myxoma and vaccinia viruses bind differentially to human leukocytes.Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits.Evolution of viral sensing RIG-I-like receptor genes in Leporidae genera Oryctolagus, Sylvilagus, and Lepus.Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.
P2860
Q26852421-3EB5A71A-BAC7-490E-8064-29A726F34EEEQ30499249-D4FCE163-F5C2-456B-9CD7-4830BB133996Q33613734-85CE156B-8646-479D-838A-54333A9CAB9DQ34380801-057C453F-5399-4E7E-8598-E2D89CE11001Q34770719-5E6356F9-CADA-4476-BD10-E5F1E71129AAQ35000601-942A74CD-57D5-4E23-80F6-ECAEF009546CQ35234349-261D246E-68FC-43A6-A901-6CED74E8F1BBQ35531431-49659678-F75A-4FA6-BFD8-F2CD1589567EQ35785529-3BFB7187-6F9F-4CE0-A494-ACD4AC555794Q37126088-40508BF9-1D2D-4729-B006-73E43FB4BB45Q37676089-72513AED-6B0E-4DF8-AA2E-3CF20183EEF6Q37887080-6AB3F4F6-839E-4FD1-BF15-8B8CE6AD9494Q38961205-35CE0EB9-E6FC-4206-A1C5-002C440661C0Q39198482-AB4F34E6-DB4A-4E5E-9A77-BC5219F9AF7BQ39387769-0FA4329F-7B0E-4875-A385-07C49B7681D8Q42256141-1C63C153-9BC0-41A9-AA25-A0B58687AA57Q44837303-8AFB46EA-24DB-4B79-926F-F564CE92CF20
P2860
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The immunoregulatory propertie ...... implications in therapeutics.
@en
The immunoregulatory propertie ...... implications in therapeutics.
@nl
type
label
The immunoregulatory propertie ...... implications in therapeutics.
@en
The immunoregulatory propertie ...... implications in therapeutics.
@nl
prefLabel
The immunoregulatory propertie ...... implications in therapeutics.
@en
The immunoregulatory propertie ...... implications in therapeutics.
@nl
P2860
P1476
The immunoregulatory propertie ...... r implications in therapeutics
@en
P2093
Sonia Wennier
P2860
P304
P356
10.1016/J.MICINF.2010.08.012
P577
2010-09-09T00:00:00Z